Inotek to Host First Research and Development Day in New York City on December 17th, 2015

– Program to Feature Key Opinion Leaders in Ophthalmology –

LEXINGTON, Mass.–(BUSINESS WIRE)–Inotek
Pharmaceuticals Corporation
(NASDAQ: ITEK), a clinical stage
biopharmaceutical company focused on the discovery, development and
commercialization of therapies for ocular diseases, today announced that
it will host its first R&D Day on Thursday, December 17, 2015, from
10:00 a.m. to 1:30 p.m. EST in New York City. Members of the Inotek
management team and distinguished guest speakers will provide an
overview of glaucoma and other optic nerve neuropathies, and the
Company’s lead product candidate, trabodenoson, a first-in-class
selective adenosine mimetic currently in Phase 3 development.

Presenting and/or participating in the event:

Key opinion leaders:

  • Craig E. Crosson, Ph.D., Professor of Ophthalmology and Senior
    Associate Dean for Research, College of Medicine, Medical University
    of South Carolina
  • L. Jay Katz, M.D., Professor of Ophthalmology, Jefferson Medical
    College, Director, Glaucoma Service, Wills Eye Hospital
  • Leonard A. Levin, M.D., Ph.D., Professor and Chair of Ophthalmology,
    McGill University, Professor of Ophthalmology and Visual Sciences,
    University of Wisconsin
  • Jonathan S. Myers, M.D., Associate Professor of Ophthalmology,
    Jefferson Medical College, Director of Glaucoma Fellowship, Wills Eye
    Hospital
  • Robert C. Sergott, M.D., Professor of Ophthalmology, Neurology, and
    Neurosurgery, Jefferson Medical College, Director, Neuro-Ophthalmology
    Service, Wills Eye Hospital

Inotek leadership team:

  • Rudolf Baumgartner, M.D., Executive Vice President & Chief Medical
    Officer
  • William McVicar, Ph.D., Executive Vice President & Chief Scientific
    Officer
  • Claudine Prowse, Ph.D., Vice President, Strategy and Investor
    Relations Officer
  • Cadmus Rich, M.D., M.B.A., Vice President Clinical Development and
    Medical Affairs
  • David Southwell, President and Chief Executive Officer

Event registration is required and attendance is limited to members of
the professional investment community. To register or learn more about
the Inotek R&D Day, please contact Claudine Prowse at 781-552-4314 or cprowse@inotekpharma.com.

Webcast and Conference Call Details
A live and archived
audio webcast can be accessed by visiting the Investors section of the
Company’s website at www.inotekpharma.com.

To participate by telephone, please dial (866) 430-2017 (Domestic) or
(704) 908-0413 (International) at least five minutes prior to the start
of the event and provide the conference ID 90883071.

About Inotek Pharmaceuticals Corporation
Inotek
Pharmaceuticals is a clinical stage biopharmaceutical company focused on
the discovery, development and commercialization of therapies for
glaucoma and other eye diseases. The Company’s lead product candidate, trabodenoson,
is a first-in-class selective adenosine mimetic currently in Phase 3
development. Trabodenoson was developed in Inotek’s laboratories
and designed to restore the eye’s natural pressure control mechanism.
The development of trabodenoson monotherapy delivered in a
once-daily eye drop formulation will be followed by a fixed-dose
combination of trabodenoson with latanoprost.
Additionally, the Company is evaluating the potential for selective
adenosine mimetics to address optic neuropathies and other degenerative
retinal diseases. For more information, please visit www.inotekpharma.com.

Contacts

Inotek Contact:
Inotek Pharmaceuticals Corporation
Claudine
Prowse, Ph.D., 781-552-4305
Vice President, Strategy and Investor
Relations Officer
cprowse@inotekpharma.com
or
Media
Contact:

MacDougall Biomedical Communications
Karen
Sharma, 781-235-3060